Lymphoma Diagnosis and Treatment

Targeting Aberrant FGFR Signaling with Infigratinib Enhances the Efficacy of BTK/PI3K Inhibitors and Bendamustine in Lymphoma Cells

This study shows that combining infigratinib with BTK/PI3K inhibitors or bendamustine improves efficacy in lymphoma cell models, reversing resistance and suggesting FGFR inhibition as a therapeutic strategy.

Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors

This study identifies IL13 as a survival factor for Hodgkin lymphoma cells by analyzing the tumor microenvironment with spatial and single-cell resolution.

Integrating Single-Cell Biophysical and Transcriptomic Features to Resolve Functional Heterogeneity in Mantle Cell Lymphoma

This study integrates single-cell biophysical and transcriptomic data to identify clinically relevant phenotypes in mantle cell lymphoma, linking biophysical properties to gene expression and drug response.

Dual targeting of BTK and BCL2 enhances apoptosis in marginal zone lymphoma models: preclinical activity of BGB-16673 and sonrotoclax

This study evaluates the preclinical efficacy of BGB-16673 and sonrotoclax in marginal zone lymphoma models, showing enhanced apoptosis when combined.

Characterization of lymphoma models for the surface ROR1 expression

The paper characterizes ROR1 expression in B-cell lymphoma models and shows that ROR1-positive models are sensitive to a ROR1-targeting ADC.

Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma

The paper identifies prognostic biological subtypes in Mantle cell lymphoma based on genetic and transcriptomic analysis, revealing distinct molecular and immune features associated with different risk groups.

High-Throughput Screening Identifies PLK1 Inhibition as a Strategy to Potentiate BTK Blockade in Marginal Zone Lymphoma

This study identifies PLK1 inhibition as a strategy to enhance BTK blockade in MZL by overcoming resistance through transcriptomic and mechanistic analysis.

Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphoma

The Origin, Diagnosis, and Prognosis of Oligomannose-Type Diffuse Large B Cell Lymphoma

This paper identifies Mann-type DLBCL as a subtype of GCB-DLBCL characterized by oligomannose-type glycans in CDR-located AGS, associated with poor prognosis and distinct gene expression patterns.

Inhibition of Mantle Cell Lymphomas by the beta 2-Adrenergic Agonist, Levalbuterol, in Hollow Fiber Assay in Mice

This study tests levalbuterol's anti-lymphoma effects in mice, finding significant inhibition of Mantle Cell lymphoma proliferation at higher concentrations.

Novel Driver Mutations in GCB Lymphoma Patients That Affect Transcription Factors Binding

The paper identifies mutation blocks in GCB lymphoma patients that affect transcription factor binding and gene expression, linking them to cancer development.

YX0798 Is a Highly Potent, Selective, and Orally Effective CDK9 Inhibitor for Treating Aggressive Lymphoma

This paper identifies YX0798 as a potent, selective, and orally effective CDK9 inhibitor that overcomes therapeutic resistance in lymphoma by inducing transcription reprogramming and cell death.

Distinct Response Patterns to PHB Modulators in B Cell Lymphoma Models

The paper evaluates five PHB-targeting molecules in B cell lymphoma models, showing varied antiproliferative and cytotoxic effects across different cell lines.

B cell receptor silencing reveals the origin of high-grade B cell lymphomas with MYC and BCL2 rearrangements

This paper shows that high-grade B cell lymphomas with MYC and BCL2 rearrangements originate from BCR-silenced follicular lymphoma cells that acquire IGL::MYC translocations, leading to resistance to CD79B-targeting therapy.

Exploring the Anti-Tumor Effects of Brusatol in Aggressive B-Cell Lymphomas

This study investigates brusatol's anti-tumor effects on aggressive B-cell lymphomas, showing it inhibits growth and induces cell death, especially when combined with venetoclax.

Multidimensional characterization of cellular ecosystems in Hodgkin lymphoma

This study identifies four molecular subtypes of Hodgkin lymphoma using multimodal data, revealing distinct clinical features and immune ecosystem dynamics.

A Novel CREBBP/p300 Activator, YF2, Enhances Cytotoxic and Immune-Mediated Responses in B-Cell Lymphoma

This paper evaluates YF2, a CREBBP/p300 activator, showing it enhances cytotoxicity and immune responses in B-cell lymphoma by restoring acetylation and altering the immune microenvironment.

DNA replication stress-induced transcriptome of Human Burkitt lymphoma identifies MBD1 as a novel suppressor of BCL6 rearrangements in germinal center derived B-lymphomagenesis

This study identifies MBD1 as a suppressor of BCL6 rearrangements in Burkitt lymphoma by regulating DNA methylation and genomic stability during DNA replication stress.

Diverse transcriptomic and mutational patterns but limited functional pathway alterations in patient-derived SS cells

The paper analyzes patient-derived SS cells to identify transcriptomic, mutational patterns, and functional pathway alterations, finding limited pathway changes but potential for MALT1 inhibition in therapy.

A High-Throughput Bone Marrow 3D Co-Culture System to Develop Resistance to B Cell Receptor Signaling Targeted Agents in B Cell Non-Hodgkin Lymphoma

This paper develops a 3D co-culture system using bone marrow stromal cells to study drug resistance in B cell non-Hodgkin lymphoma and identifies potential resistance mediators.

Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of Diffuse Large B Cell Lymphoma

This study shows that targeting DOT1L and EZH2 together disrupts the germinal center identity of GCB-DLBCL cells, leading to a cell-identity crisis and reduced tumor growth in vivo.

SL/Kh Pre-B Lymphomas Originate in the Thymus and are a Model for Primary Mediastinal (Thymic) Large B-Cell Lymphoma

This paper identifies thymus-origin pre-B lymphomas in SL/Kh mice and links them to human mediastinal large B-cell lymphoma through Notch1 signaling and retroviral mutagenesis.

Small molecule inhibitor combination treatment effectively represses global B-cell signaling in diffuse large B-cell lymphoma

The paper shows that combining three inhibitors represses B-cell signaling more effectively than single inhibitors in diffuse large B-cell lymphoma.

Multi-modal profiling identifies CD4+CXCR5+PD-1- Tfh cells as prognostic and predictive biomarkers for response to R-CHOP therapy in human DLBCL

The paper identifies CD4+CXCR5+PD-1- Tfh cells as prognostic and predictive biomarkers for R-CHOP therapy response in DLBCL using single-cell RNA sequencing and multiplex IHC.

Immune Cell Influence on Diffuse Large B-Cell Lymphoma: A Mendelian Randomization Analysis

This study uses Mendelian randomization to identify seventeen immune cell features with causal links to diffuse large B-cell lymphoma and finds a reverse causal relationship between DLBCL and one immune cell type.

IgSeqR: a protocol for the identification, assembly, and characterization of full-length tumor Immunoglobulin transcripts from unselected RNA sequencing data

The paper introduces a protocol for extracting and characterizing full-length tumor immunoglobulin transcripts from RNA-seq data, enabling analysis of their sequences and potential clinical applications.

Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies

This study investigates how PIK3CA gain and PTEN loss affect MCL biology and drug response, finding reduced BCR dependence and increased therapy resistance.

Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing data.

Detection of disease-specific signatures in B cell repertoires of lymphomas using machine learning

This paper uses machine learning to classify B cell lymphomas based on BCR repertoire sequencing, achieving high accuracy in distinguishing between subtypes.

Deep Visual Proteomics Unveils Precision Medicine Insights in Composite Small Lymphocytic and Classical Hodgkin Lymphoma

This study uses Deep Visual Proteomics to analyze proteomic profiles in composite Hodgkin and small lymphocytic lymphomas, identifying subtype-specific treatment strategies.